WHO ICTRP trial
A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY…
EUCTR2008-006939-13-FR · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2008-006939-13-FR |
|---|---|
| Public title | A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND ACTIVITY OF MetMAb, A MONOVALENT ANTAGONIST ANTIBODY TO THE RECEPTOR MET, ADMINISTERED TO PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH TARCEVA®(ERLOTINIB) |
| Scientific title | A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND ACTIVITY OF MetMAb, A MONOVALENT ANTAGONIST ANTIBODY TO THE RECEPTOR MET, ADMINISTERED TO PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH TARCEVA®(ERLOTINIB) |
| Primary sponsor | Genentech, Inc. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | France;Poland |
| Conditions | Patients with advanced non-small cell lung cancer MedDRA version: 9.1 Level: PT Classification code 10061873 Term: Non-small cell lung cancer |
| Interventions | Product Name: MetMAb Pharmaceutical Form: Concentrate for solution for infusion Current Sponsor code: OA5D5; rhuMabOA5D5; PRO143966 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 60mg/ml… |
| Registration date | Jan 4, 2009 |
| Target size | 120 |
| Secondary IDs | OAM4558g |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: